Sanofi S.A.
Financial Performance
Sanofi Revenue & Financials
Revenue
~$49.3B (FY2025)
Market Cap
$100B
Net Income
~$8.8B
Employees
74,846
What is Sanofi's revenue?
Sanofi had ~$49.3B in revenue for fiscal year 2025, up 6.2% from 2024. Net income was ~$8.8B.
- Latest revenue
- ~$49.3B (FY2025)
- Year-over-year
- +6.2%
- Growth rate (CAGR)
- 2.7% over 4 years
- Peak revenue
- ~$49.3B (FY2025)
- Years of data
- 5
- Employees
- 74,846
- How much profit does Sanofi make?
- Sanofi reported net income of ~$8.8B for fiscal year 2025. sanofi.com
- How many employees does Sanofi have?
- Sanofi has about 74,846 employees.
Financial Analysis
Sanofi's finances now hinge on Dupixent. Sales of the antibody reached ~$17.7 billion (EUR15.7 billion) in 2025 and ~$5.88 billion (EUR5.2 billion) in Q2 2026 alone, up 37.6%, and management has targeted around $24.9 billion (EUR22 billion) by 2030. Group net sales grew from ~$46.4 billion (EUR41.081 billion) in 2024 to ~$49.3 billion (EUR43.626 billion) in 2025, free cash flow was about $9.15 billion (EUR8.1 billion), and Q2 2026 business EPS rose 33.3% at CER to EUR2.09. The 2025 Opella deal turned the consumer business into a 48.2% equity stake and brought in cash that Sanofi used for acquisitions such as Blueprint Medicines and share buybacks. Sanofi is a colossal French multinational pharmaceutical and healthcare company, commanding a massive market valuation generally exceeding $130 billion.
Revenue Trend Analysis
YoY Change
+6.2%
4-Year CAGR
+2.7%
Peak Year
2025
Trend
Consistent Growth
Sanofi S.A. has 5 full fiscal year figures on this page, compounding at +2.7% annually over 4 years. The most recent year saw a 6.2% increase versus the prior year. Annual revenue peaked in fiscal year 2025 at ~$49.3B. Of 4 comparable year-over-year steps, 3 showed growth and 1 showed a decline.
Annual revenue history
| Fiscal Year | Revenue | Net Income | YoY Change | Source |
|---|---|---|---|---|
| FY2025 | ~$49.3B | ~$8.8B | +6.2% | Sanofi Q4 and FY2025 results Net sales +9.9% at CER, +6.2% reported. Dupixent ~$17.7B (EUR15.7B). |
| FY2024 | ~$46.4B | ~$6.3B | +8.6% | Sanofi Q4 and FY2024 results Net sales excluding Opella; +11.3% at CER. |
| FY2023 | ~$42.7B | ~$6.1B | -6.2% | Sanofi FY2025 Form 20-F Net sales restated to exclude Opella (consumer healthcare). |
| FY2022 | ~$45.5B | ~$9.5B | +2.9% | Sanofi annual reports via StockAnalysis (S&P Global) Total revenue as originally reported, including Consumer Healthcare. |
| FY2021 | ~$44.3B | ~$7B | — | Sanofi annual reports via StockAnalysis (S&P Global) Total revenue as originally reported, including Consumer Healthcare. |
Click any row to see year details.
Keep researching Sanofi
Sanofi Revenue and Financial FAQ
What was Sanofi's revenue performance in 2023 and 2024?
Sanofi generated net sales of €43.07 billion (approx. $47 billion) in 2023 (up 5.3% at constant exchange rates) and expanded past €44 billion to €46 billion in 2024, powered by double-digit volume growth in Dupixent and new vaccine launches.
What is Sanofi's Business Operating Income (BOI) and operating margin?
Sanofi delivered Business Operating Income of €11.6 billion in 2023 with an operating margin of 27.0%, generating Business Earnings Per Share (EPS) of €7.25, with margins expected to approach 30% following the deconsolidation of Opella.
How fast are Dupixent sales growing on Sanofi's income statement?
Dupixent generated €10.72 billion in net sales in 2023 (up 34% YoY) and crossed €13 billion annualized in 2024, with peak sales guidance targeting well over €15 billion following approval for Chronic Obstructive Pulmonary Disease (COPD).
What is Sanofi's dividend track record and payout yield?
Sanofi is one of Europe's top dividend payers, having increased its annual cash dividend for 29 consecutive years, paying €3.76 per share in 2024, offering a resilient dividend yield between 4.0% and 4.8%, distributing over €4.7 billion annually to shareholders.
What are the financial implications of the Opella transaction for Sanofi's balance sheet?
The sale of a 50% stake in Opella to CD&R generates approximately €8 billion to €9 billion in upfront net cash proceeds for Sanofi, substantially deleveraging the balance sheet and funding pipeline acquisitions and share buybacks.
How much free cash flow does Sanofi generate annually?
Sanofi generates approximately €8.0 billion to €9.0 billion in annual operating cash flow and over €6.0 billion to €7.0 billion in free cash flow, providing immense self-funding flexibility for clinical trials.
What is Sanofi's debt profile and credit rating?
Sanofi holds an AA- / A1 investment-grade credit rating with net debt of approximately €8.5 billion, representing a conservative net debt to EBITDA ratio well below 1.0x, giving it one of the cleanest balance sheets in global pharma.
How did the unexpected R&D budget increase in late 2023 impact Sanofi stock?
In October 2023, CEO Paul Hudson announced that Sanofi would abandon its short-term 32% margin target to invest an additional €700M+ annually into 12 potential blockbuster Phase 3 clinical trials. The announcement caused a one-day 15% stock drop before shares rebounded as clinical data matured.
How much revenue does Sanofi Vaccines generate annually?
Sanofi Vaccines generates approximately €7.5 billion to €8.0 billion annually, led by seasonal flu vaccines (€2.7B+) and rapid commercial acceleration of Beyfortus (€1.2B+ in its first full year).
What are Sanofi's capital expenditure commitments?
Sanofi invests roughly €2.0 billion to €2.5 billion annually in capex, funding state-of-the-art modular "Evolv" biomanufacturing plants in Neuville-sur-Saône (France) and Singapore capable of switching production between 3-4 different vaccines or biologics simultaneously.
What share buyback programs does Sanofi execute?
Sanofi routinely executes opportunistic share buyback programs to neutralize share issuance from employee equity schemes, with management indicating potential expanded share repurchases following Opella transaction closing.
What is Sanofi's market capitalization and index weighting?
Sanofi trades on Euronext Paris (ticker: SAN) and as ADRs on NASDAQ (ticker: SNY), commanding a market capitalization between €110 billion and €130 billion ($120B-$140B), representing one of the top five largest constituents of the benchmark CAC 40 index.
Cite or embed this data
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Sanofi Revenue & Financials." CorpDigest, https://corpdigest.com/company/sanofi/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Sanofi reported ~$49.3B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/sanofi/financials" target="_blank" rel="noopener">CorpDigest — Sanofi financials</a></div>Related Financial Audits
Compare revenue, net income, and market cap scale
Explore Sanofi
Core profile pages, founders and related research hubs for this company.